Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis
暂无分享,去创建一个
F. Balloux | L. van Dorp | M. Acman | J. Pang | A. Ortiz | N. Padayatchi | O. Brynildsrud | J. Millard | A. Grant | Camus Nimmo | Vegard Eldholm | Louis Grandjean | C. C. Tan | Xavier Didelot | Max O’Donnell | Alex Pym
[1] A. Witney,et al. Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid , 2023, PLOS global public health.
[2] C. Köser,et al. Minimum inhibitory concentrations and sequencing data have to be analysed in more detail to set provisional epidemiological cut-off values for Mycobacterium tuberculosis complex , 2023, European Respiratory Journal.
[3] J. Turnidge,et al. The determination of epidemiological cut-off values requires a systematic and joint approach based on quality controlled, non-truncated minimum inhibitory concentration series , 2023, European Respiratory Journal.
[4] Daniel J. Wilson,et al. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis , 2023, The Lancet. Microbe.
[5] A. Crook,et al. Treatment Strategy for Rifampin-Susceptible Tuberculosis. , 2023, The New England journal of medicine.
[6] Z. Iqbal,et al. Repeated evolution of bedaquiline resistance in Mycobacterium tuberculosis is driven by truncation of mmpR5 , 2022, bioRxiv.
[7] A. Crook,et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. , 2022, The New England journal of medicine.
[8] M. DeJesus,et al. Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis , 2022, Antimicrobial agents and chemotherapy.
[9] Z. Iqbal,et al. A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics , 2022, PLoS biology.
[10] K. Fielding,et al. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis , 2022, Trials.
[11] A. Van Rie,et al. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis , 2021, The Lancet. Microbe.
[12] L. Freschi,et al. Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex , 2021, bioRxiv.
[13] P. Fowler. Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis , 2021, European Respiratory Journal.
[14] B. D. de Jong,et al. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era , 2020, Genome medicine.
[15] J. Sacchettini,et al. Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis , 2020, Antimicrobial Agents and Chemotherapy.
[16] F. Balloux,et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis , 2020, The Lancet. Microbe.
[17] Y. Pang,et al. Reduced susceptibility of Mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] C. Köser,et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. , 2020, The Journal of antimicrobial chemotherapy.
[19] M. Matsumoto,et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor , 2020, Antimicrobial Agents and Chemotherapy.
[20] J. Parkhill,et al. Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex , 2020, Genome Medicine.
[21] F. Balloux,et al. Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients , 2020, European Respiratory Journal.
[22] S. Niemann,et al. Bedaquiline-resistant Tuberculosis: Dark Clouds on the Horizon. , 2020, American journal of respiratory and critical care medicine.
[23] F. Balloux,et al. Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment , 2020, EBioMedicine.
[24] L. Rigouts,et al. An African origin for Mycobacterium bovis , 2019, bioRxiv.
[25] S. Niemann,et al. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] V. Eldholm,et al. Lineage specific histories of Mycobacterium tuberculosis dispersal in Africa and Eurasia , 2019, Molecular ecology.
[27] Jim F Huggett,et al. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs , 2019, Genome Medicine.
[28] I. Mokrousov,et al. Acquisition of bedaquiline resistance by extensively drug resistant Mycobacterium tuberculosis strain of Central Asian Outbreak clade. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[29] A. Ghafoor,et al. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan , 2019, Antimicrobial Agents and Chemotherapy.
[30] D. Brites,et al. The molecular clock of Mycobacterium tuberculosis , 2019, bioRxiv.
[31] R. Peters,et al. Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance , 2019, Antimicrobial Agents and Chemotherapy.
[32] Phelim Bradley,et al. Ultra-fast search of all deposited bacterial and viral genomic data , 2019, Nature Biotechnology.
[33] A. Fateh,et al. High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness , 2019, Antimicrobial Agents and Chemotherapy.
[34] Sebastián Duchêne,et al. BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis , 2018, bioRxiv.
[35] Nalini Singh,et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen , 2018, European Respiratory Journal.
[36] F. Balloux,et al. Whole genome sequencing Mycobacterium tuberculosis directly from sputum identifies more genetic diversity than sequencing from culture , 2018, BMC Genomics.
[37] Alexey M. Kozlov,et al. RAxML-NG: a fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference , 2018, bioRxiv.
[38] T. Clark,et al. Global expansion of Mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation , 2018, Science Advances.
[39] R. Peters,et al. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis , 2018, Data in brief.
[40] Sebastian M. Gygli,et al. Multiple Introductions of the Mycobacterium tuberculosis Lineage 2–Beijing into Africa over centuries , 2018, bioRxiv.
[41] T. Clark,et al. Identifying mixed Mycobacterium tuberculosis infections from whole genome sequence data , 2018, BMC Genomics.
[42] Emmanuel Paradis,et al. ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R , 2018, Bioinform..
[43] V. Sintchenko,et al. Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia. , 2018, Tuberculosis.
[44] P. Rancoita,et al. Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis , 2018, Antimicrobial Agents and Chemotherapy.
[45] Daniel J. Wilson,et al. Bayesian inference of ancestral dates on bacterial phylogenetic trees , 2018, bioRxiv.
[46] K. Dheda,et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa , 2018, European Respiratory Journal.
[47] Christian Beisel,et al. Treemmer: a tool to reduce large phylogenetic datasets with minimal loss of diversity , 2018, BMC Bioinformatics.
[48] C. Fraser,et al. Convergent evolution and topologically disruptive polymorphisms among multidrug-resistant tuberculosis in Peru , 2017, PloS one.
[49] O. Antonova,et al. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region , 2017, The Journal of antimicrobial chemotherapy.
[50] Alimuddin Zumla,et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study , 2017, European Respiratory Journal.
[51] T. Clark,et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. , 2017, The Lancet. Respiratory medicine.
[52] Bin Wang,et al. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis , 2017, Antimicrobial Agents and Chemotherapy.
[53] Y. Yazdanpanah,et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis , 2017, European Respiratory Journal.
[54] T. Tønjum,et al. Tuberculosis Outbreak in an Educational Institution in Norway , 2017, Journal of Clinical Microbiology.
[55] Thomas Abeel,et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into emergence and spread of multidrug resistance , 2017, Nature Genetics.
[56] Guangchuang Yu,et al. ggtree: an r package for visualization and annotation of phylogenetic trees with their covariates and other associated data , 2017 .
[57] L. Rigouts,et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline , 2016, The Journal of antimicrobial chemotherapy.
[58] F. Balloux,et al. Antimicrobial Resistance in Mycobacterium tuberculosis: The Odd One Out. , 2016, Trends in microbiology.
[59] Koen Andries,et al. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis , 2016, Antimicrobial Agents and Chemotherapy.
[60] Simon R. Harris,et al. SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments , 2016, bioRxiv.
[61] Phelim Bradley,et al. Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis , 2015, Nature Communications.
[62] A. Diacon,et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis , 2015, European Respiratory Journal.
[63] G. Bloemberg,et al. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. , 2015, The New England journal of medicine.
[64] Carmen Z. Suarez,et al. Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[65] Ana Conesa,et al. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data , 2015, Bioinform..
[66] K. Dheda,et al. Molecular Epidemiological Interpretation of the Epidemic of Extensively Drug-Resistant Tuberculosis in South Africa , 2015, Journal of Clinical Microbiology.
[67] Thomas Abeel,et al. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal , 2015, PLoS medicine.
[68] Gang Sun,et al. Southern East Asian origin and coexpansion of Mycobacterium tuberculosis Beijing family with Han Chinese , 2015, Proceedings of the National Academy of Sciences.
[69] R. Bouckaert,et al. bModelTest: Bayesian phylogenetic site model averaging and model comparison , 2015, BMC Evolutionary Biology.
[70] C. Dye,et al. Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study , 2015, PLoS medicine.
[71] Francesc Coll,et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences , 2015, Genome Medicine.
[72] Nalin Rastogi,et al. The Association between Mycobacterium Tuberculosis Genotype and Drug Resistance in Peru , 2015, PloS one.
[73] Gemma L. Kay,et al. Eighteenth-century genomes show that mixed infections were common at time of peak tuberculosis in Europe , 2015, Nature Communications.
[74] J. Parkhill,et al. Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area , 2015, eLife.
[75] Nalin Rastogi,et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage , 2015, Nature Genetics.
[76] Francesc Coll,et al. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains , 2014, Nature Communications.
[77] Eduardo Gotuzzo,et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. , 2014, The New England journal of medicine.
[78] B. D. de Jong,et al. Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline , 2014, PloS one.
[79] S. Cole,et al. Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.
[80] Mauricio O. Carneiro,et al. From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.
[81] Heng Li. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.
[82] M. Suchard,et al. Improving the accuracy of demographic and molecular clock model comparison while accommodating phylogenetic uncertainty. , 2012, Molecular biology and evolution.
[83] D. Froese,et al. Antibiotic resistance is ancient , 2011, Nature.
[84] K. Andries,et al. Rates and Mechanisms of Resistance Development in Mycobacterium tuberculosis to a Novel Diarylquinoline ATP Synthase Inhibitor , 2009, Antimicrobial Agents and Chemotherapy.
[85] Hinrich W. H. Göhlmann,et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.
[86] THE WORLD HEALTH ORGANIZATION , 1954 .
[87] Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium , 2022 .
[88] OUP accepted manuscript , 2022, Journal of Antimicrobial Chemotherapy.